O&D-001

N/A

Report date: 2026/01/29 20:00:06

Base Information

Drug NameO&D-001
Drug Alias NameO&D-001
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-cell maturation protein modulatorsG-protein coupled receptor family C group 5member D modulators
TargetsB-cell maturation proteinG-protein coupled receptor family C group 5member D
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesO&D BioTech Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesO&D BioTech Group Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A